RxDoctor Payments Data

Kirsti Roehm, OD

Optometrist · St Petersburg, FLNPI 1447788419

Payments from drug & device makers

$1,702in general payments, 2019–2025

Across 23 payments — averaging $74.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$384
  • AbbVie$267
  • Johnson & Johnson Surgical Vision, Inc.$195
  • Sight Sciences, Inc.$166
  • Rxsight Inc$161
  • Ocular Therapeutix, Inc.$127
  • plus $403 from 8 others

What the payments were for

  • Travel & lodging$533%
  • Food & beverage$1,64997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,702 in reported general payments places this provider in the 65th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$147,644
Medicare patients
732
Services billed
1,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine64$81,222
LumiganBimatoprost36$21,386
CombiganBrimonidine Tartrate/Timolol19$10,643
Cyclosporine17$8,571
Latanoprost468$5,401
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$2,383
Travoprost11$1,822
Timolol Maleate161$1,743
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,485
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat137$1,356
Dorzolamide Hcl70$1,301
Prednisolone Acetate40$1,146
Brimonidine Tartrate71$671
ErythromycinErythromycin Base15$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$267$113,251119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,166 optometrist providers in Florida.

Other optometrist in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →